We are live on ! Find out more
OTLKW

Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW

Delisted

OTLKW was delisted on the 16th of February, 2022.

Back to rankings

4 hedge funds and large institutions have $61K invested in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 in 2021 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 4 → 4 (0)

47% less capital invested

Capital invested by funds: $116K → $61K (-$55K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
–
Calls
$171K
Puts
–
Net Calls
+$171K
Net Calls Change
-$101K

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$8.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
1
Cormorant Asset Management
Massachusetts
$32K – – –
SFM
2
Sphera Funds Management
Israel
$15K – – –
PC
3
PointState Capital
New York
$10K – – –
Susquehanna International Group
4
Susquehanna International Group
Pennsylvania
$4K -$8.4K -48,061 -61%

OTLKW Hedge Fund Activity: Q4 2021 in Review

4 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) for Q4 2021, worth a combined $61K — down 47% from $116K a quarter earlier.

Fund positioning in OTLKW was balanced in Q4 2021: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.

The largest seller was Susquehanna International Group, cutting an estimated $8.4K.

  • 4 institutional investors held Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) as of Q4 2021, unchanged from Q3 2021.
  • Funds reported $61K of Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 stock for Q4 2021, down 47% quarter-over-quarter.
  • 0 funds opened new Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 positions in Q4 2021 and 0 closed out.
  • The largest Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 seller in Q4 2021 was Susquehanna International Group, an estimated $8.4K sold.

Based on aggregated 13F filings for Q4 2021.